| The
American Association for the Treatment of Opioid Dependence works
with federal agencies and state substance abuse authorities concerning
opioid treatment policy. The Association developed the State Methadone
Guidelines (1993) and conjunction with the American Society of Addiction
Medicine (ASAM) for the Center for Substance Abuse Treatment (CSAT).
These guidelines have been translated into French, Italian and Spanish
and distributed to more than 20 countries. (Remove:The Association
is presently assisting CSAT in the development of an updated, encyclopedic
Opioid Treatment Improvement Protocol (TIP), Medication Assisted
Treatment for Opioid Treatment for Opioid Addiction.
Currently,
the methadone treatment system is experiencing major changes as
accreditation is implemented as the new federal oversight standard.
AATOD continues to work with federal and state agencies to assist
our members on complying with these standards, ensuring that they
receive technical assistance necessary to make the transition. We
believe that accreditation is a positive change for our field, improving
the quality of health care in our facilities, increasing the legitimacy
of the treatment system and greatly reducing the stigma often associated
with our field.
Most
recently, the Association worked with the National Drug Court Institute
(NDCI) to publish and distribute the Drug
Court Practitioner Fact Sheet, providing a basic understanding
of opioid treatment for drug court professionals. The Association
also worked recently with the Drug Enforcement Administration (DEA)
to produce the Best Practice Guideline for Narcotic Treatment Programs
and the Substance Abuse and Mental Health Services Administration/Center
for Substance Abuse Treatment (SAMHSA/ CSAT) in producing the Community
Education Kit: Medication Assisted Treatment for the 21st Century.)
The
Association also convenes national conferences on an
eighteen-month cycle. These conferences focus on evidence-based
clinical practice, current research breakthroughs and organizational
developments affecting the current and future opioid treatment system.
More than 46 states and 21 countries send representatives to this
event. The National Institute on Drug Abuse (NIDA) in addition to
SAMHSA/ CSAT and other federal agencies work to support a number
of the activities of this conference, including international relations
and domestic substance abuse policy. The State Opioid Treatment
Authorities meet during this event, working through policy related
issues in their respective states.
AATOD
has been working with partners in the criminal justice system for
the past ten years and have featured a number of plenary sessions
during our national conferences on this topic. We have secured grants
from various groups over the years in support of this policy initiative
including the grant from the Robert Wood Johnson Foundation and
Covidien Mallinckrodt and more recently, from Reckitt-Benckiser.
AATOD, through its research partners at the National Development
and Research Institutes in New York and Brown University in Rhode
Island , have been working with our policy partners in the criminal
justice system on an attitudinal survey towards the use of medication-assisted
treatment of chronic opioid addiction. This would be a foundation
document in working with the appropriate federal agencies to increase
access to federally approved medications to treat chronic opioid
addiction through drug courts, correctional facilities, and through
probation and parole officers.
AATOD
is also working with a number of policy partners to work with the
Alliance of States with Prescription Monitoring Programs (PMPs)
and the Brandeis University PMP Center of Excellence in developing
a series of policy recommendations for our associates through the
OTPs in the U.S. to gain access to PMP databases without compromising
federal confidentiality protections for our patients. Ultimately,
we believe that Prescription Monitoring Programs serve as a valuable
clinical tool in better informing clinicians about how to more safely
and effectively treat our patients.
AATOD
continues to work with the recognized Patient Advocacy Organizations
in educating providers and the treatment community. We have worked
most specifically with NAMA Recovery, based in New York City , as
a means of coordinating the work of many Patient Advocacy Organizations
throughout the United States to promote the value of recovery as
patients enter the treatment process. We believe that working with
patient advocates is critical to the future of our treatment system
especially as we promote recovery-based models of care.
We
have been working with our associates in EUROPAD since 1989 and
entered into a formal relationship during July 2007 when AATOD and
EUROPAD founded the World Federation for the Treatment of Opioid
Dependence. These two groups recently submitted an application to
the United Nations to receive a Non-Government Organizational status
to promote the development of medication-assisted treatment for
opioid addiction wherever it is needed throughout the world. This
application was accepted during the first quarter of 2011, enabling
the World Federation to work with the United Nations and its member
organizations and nations as a means of achieving the objectives
of expanding access to care for opioid addiction following evidence-based
practice and good clinical guidelines.
AATOD
is also working with SAMHSA/CSAT in all of the designated federal
agencies as health care reform is implemented to increase insurance
coverage for more than 30 million Americans. This will also include
a significant number of people who are opioid addicted and will
need access to care through OTPs throughout the United States .
We are especially pleased to be working with the Legal Action Center
, a long-standing policy partner, in developing effective models
of delivery in order to treat a new patient population, who do not
have access to care through lack of health insurance.
AATOD
is also working with treatment providers and policy officials in
a number of states as a result of increased legislative activity
in the states as a method of educating various policy officials
and lawmakers to better understand many of the current dynamics
effecting the general population as prescription opioid abuse continues
to be a major challenge in the U.S.
Our
staff and Board of Directors work tenaciously to promote the interests
of our program members but it is through the unity of all of our
policy partners in the treatment and policy community that we are
able to increase the public understanding of what we do in the treatment
system and to ensure that all who need access to care receive it.

|